BGN and neoplasm: A further investigation of myoferlin in the context of tumor-restraining ECM components, such as collagen XV (Clementz et al, 2013) and biglycan (Weber et al, 2001) is necessary to validate a specific tumor-promoting ECM function of myoferlin.